Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penehyclidine for prevention of postoperative nausea and vomiting following temporomandibular joint surgery
ChiCTR2400089370Phase 4Not yet recruiting
- Sponsor
- Affiliated Stomatological Hospital of Nanjing Medical University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of penehyclidine in postoperative nausea and vomiting (PONV) and temporomandibular joint disc displacement without reduction (DDwoR) (2 arms), sponsored by Affiliated Stomatological Hospital of Nanjing Medical University. Primary endpoint: Incidence of postoperative nausea and vomiting (PONV). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
penehyclidine
03
Conditions
postoperative nausea and vomiting (PONV)temporomandibular joint disc displacement without reduction (DDwoR)
Beyond the preview
Go deeper on ChiCTR2400089370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089370.